Skip to search formSkip to main content
You are currently offline. Some features of the site may not work correctly.

Cotara

National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Review
2013
Review
2013
  • M. Parseghian
  • Biochemistry and cell biology = Biochimie et…
  • 2013
  • Corpus ID: 2810987
Questionable data and poor antibody performance may have a common factor: antigens "hitchhiking" on the very antibodies designed… Expand
  • table 1
  • table 2
  • table 3
  • table 4
  • figure 2
Review
2012
Review
2012
The prognosis for patients with malignant gliomas remains poor, and novel treatment paradigms are needed. Radioimmunotherapeutic… Expand
2012
2012
Proceedings: AACR 103rd Annual Meeting 2012‐‐ Mar 31‐Apr 4, 2012; Chicago, IL Tumors contain both microscopic and macroscopic… Expand
Review
2011
Review
2011
Introduction: Despite treatment advances for malignant gliomas in adults, prognosis remains poor, largely due to the infiltrative… Expand
2011
2011
2035 Background: GBM is the most common and clinically aggressive primary brain tumor. For recurrent GBM, treatment by surgical… Expand
2009
2009
A key limitation in developing radiotherapeutic proteins is the expense of manufacturing the drug in small batches using… Expand
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • figure 5
2008
2008
2039 Background: Interstitial 131I-chTNT-1/B MAb (Cotara) is a radioiodinated chimeric monoclonal antibody specific for DNA and… Expand
2006
2006
Treatment of malignant glioma is therapeutically challenging. Despite improvements in neurosurgery, radiotherapy and chemotherapy… Expand
2006
2006
The potential of human immunotherapeutics now revolutionizing modern cancer therapy has yet to make an impact in veterinary… Expand
Highly Cited
2005
Highly Cited
2005
OBJECTIVE: We report the safety and feasibility of using convection-enhanced delivery to administer Cotara (Peregrine… Expand
  • figure 1
  • table 1
  • table 2
  • table 3
  • table 4